Fenofibrate Reduces C-Reactive Protein Levels in Hypertriglyceridemic Patients With High Risks for Cardiovascular Diseasesopen access
- Authors
- Min, Yun Joo; Choi, Young Hwan; Hyeon, Cheol Won; Cho, Jun Hwan; Kim, Kyung Joon; Kwon, Jee Eun; Kim, Eun Young; Lee, Wang-Soo; Lee, Kwang Je; Kim, Sang-Wook; Kim, Tae Ho; Kim, Chee Jeong
- Issue Date
- Nov-2012
- Publisher
- KOREAN SOC CARDIOLOGY
- Keywords
- Fenofibric acid; C-reactive protein; Lipids; Lipoprotein
- Citation
- KOREAN CIRCULATION JOURNAL, v.42, no.11, pp 741 - 746
- Pages
- 6
- Journal Title
- KOREAN CIRCULATION JOURNAL
- Volume
- 42
- Number
- 11
- Start Page
- 741
- End Page
- 746
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20035
- DOI
- 10.4070/kcj.2012.42.11.741
- ISSN
- 1738-5520
1738-5555
- Abstract
- Background and Objectives: The effects of fenofibrate on C-reactive protein (CRP) are under debate. We investigated the effect of fenofibrate on CRP levels and the variables determining changes. Subjects and Methods: This case-control study enrolled 280 hypertriglyceridemic patients who were managed either with 200 mg of fenofibrate (Fenofibrate group, n=140) or with standard treatment (comparison group, n=140). CRP levels were measured before and after management for 2 months. Results: CRP levels decreased in both the fenofibrate (p=0.003) and comparison (p=0.048) groups. Changes in CRP levels were not significantly different between the two groups (p=0.27) and were negatively associated with baseline CRP levels (r=-0.47, p<0.001). In patients with a baseline CRP level >= 1 mg/L, CRP levels also decreased in both groups (p=0.000 and p=0.001 respectively), however, more in the fenofibrate group than in the comparison group (p=0.025). The reduction of CRP was associated with higher baseline CRP levels (r=-0.29, p=0.001), lower body mass index (BMI, r=0.23, p=0.007), and fenofibrate therapy (r=0.19, p=0.025). CRP levels decreased more in the fenofibrate group than in the comparison group in patients with a BMI <= 26 kg/m(2) with borderline significance (-1.21 +/- 1.82 mg/L vs. -0.89 +/- 1.92 mg/L, p=0.097). In patients with a high density lipoprotein-cholesterol level <40 mg/dL, CRP levels were reduced only in the fenofibrate group (p=0.006). Conclusion: Fenofibrate reduced CRP levels in hypertriglyceridemic patients with high CRP and/or low high density lipoprotein-cholesterol levels and without severe overweight. This finding suggests that fenofibrate may have an anti-inflammatory effect in selected patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/20035)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.